These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

795 related articles for article (PubMed ID: 28447912)

  • 1. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
    Gautschi O; Milia J; Filleron T; Wolf J; Carbone DP; Owen D; Camidge R; Narayanan V; Doebele RC; Besse B; Remon-Masip J; Janne PA; Awad MM; Peled N; Byoung CC; Karp DD; Van Den Heuvel M; Wakelee HA; Neal JW; Mok TSK; Yang JCH; Ou SI; Pall G; Froesch P; Zalcman G; Gandara DR; Riess JW; Velcheti V; Zeidler K; Diebold J; Früh M; Michels S; Monnet I; Popat S; Rosell R; Karachaliou N; Rothschild SI; Shih JY; Warth A; Muley T; Cabillic F; Mazières J; Drilon A
    J Clin Oncol; 2017 May; 35(13):1403-1410. PubMed ID: 28447912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.
    Ferrara R; Auger N; Auclin E; Besse B
    J Thorac Oncol; 2018 Jan; 13(1):27-45. PubMed ID: 29128428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study.
    Lu C; Dong XR; Zhao J; Zhang XC; Chen HJ; Zhou Q; Tu HY; Ai XH; Chen XF; An GL; Bai J; Shan JL; Wang YN; Yang SY; Liu X; Zhuang W; Wu HT; Zhu B; Xia XF; Chen RR; Gu DJ; Xu HM; Wu YL; Yang JJ
    J Hematol Oncol; 2020 Apr; 13(1):37. PubMed ID: 32295619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
    Drilon A; Rekhtman N; Arcila M; Wang L; Ni A; Albano M; Van Voorthuysen M; Somwar R; Smith RS; Montecalvo J; Plodkowski A; Ginsberg MS; Riely GJ; Rudin CM; Ladanyi M; Kris MG
    Lancet Oncol; 2016 Dec; 17(12):1653-1660. PubMed ID: 27825636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series.
    Ribeiro MFSA; Alessi JVM; Oliveira LJC; Gongora ABL; Sacardo KP; Zucchetti BM; Shimada AK; de Galiza Barbosa F; Feher O; Katz A
    Lung Cancer; 2020 Jan; 139():9-12. PubMed ID: 31698333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study.
    Shen T; Pu X; Wang L; Yu Z; Li J; Zhang Y; Liang X; Chen H; Xu C; Song Z; Wang W
    Clin Lung Cancer; 2020 Sep; 21(5):e349-e354. PubMed ID: 32143967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
    Roskoski R; Sadeghi-Nejad A
    Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RET fusions in solid tumors.
    Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
    Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
    Drilon A; Bergagnini I; Delasos L; Sabari J; Woo KM; Plodkowski A; Wang L; Hellmann MD; Joubert P; Sima CS; Smith R; Somwar R; Rekhtman N; Ladanyi M; Riely GJ; Kris MG
    Ann Oncol; 2016 Jul; 27(7):1286-91. PubMed ID: 27056998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.
    Drilon A; Lin JJ; Filleron T; Ni A; Milia J; Bergagnini I; Hatzoglou V; Velcheti V; Offin M; Li B; Carbone DP; Besse B; Mok T; Awad MM; Wolf J; Owen D; Camidge DR; Riely GJ; Peled N; Kris MG; Mazieres J; Gainor JF; Gautschi O
    J Thorac Oncol; 2018 Oct; 13(10):1595-1601. PubMed ID: 30017832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib.
    Mukhopadhyay S; Pennell NA; Ali SM; Ross JS; Ma PC; Velcheti V
    J Thorac Oncol; 2014 Nov; 9(11):1714-9. PubMed ID: 25436805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
    Sun F; McCoach CE
    Curr Treat Options Oncol; 2021 Jun; 22(8):72. PubMed ID: 34165651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice.
    Lee J; Ku BM; Shim JH; La Choi Y; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Jpn J Clin Oncol; 2020 May; 50(5):594-601. PubMed ID: 32083304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.
    Yoh K; Seto T; Satouchi M; Nishio M; Yamamoto N; Murakami H; Nogami N; Matsumoto S; Kohno T; Tsuta K; Tsuchihara K; Ishii G; Nomura S; Sato A; Ohtsu A; Ohe Y; Goto K
    Lancet Respir Med; 2017 Jan; 5(1):42-50. PubMed ID: 27825616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma.
    Hida T; Velcheti V; Reckamp KL; Nokihara H; Sachdev P; Kubota T; Nakada T; Dutcus CE; Ren M; Tamura T
    Lung Cancer; 2019 Dec; 138():124-130. PubMed ID: 31710864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis.
    Tsuta K; Kohno T; Yoshida A; Shimada Y; Asamura H; Furuta K; Kushima R
    Br J Cancer; 2014 Mar; 110(6):1571-8. PubMed ID: 24504365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How should "RET positive" NSCLC be treated?
    Smit EF
    Lung Cancer; 2017 Jun; 108():250-251. PubMed ID: 28189265
    [No Abstract]   [Full Text] [Related]  

  • 18. Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning.
    Song M; Kim SH; Yoon SK
    Arch Pharm Res; 2015 Dec; 38(12):2120-3. PubMed ID: 26377589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.
    Song M
    J Med Chem; 2015 May; 58(9):3672-81. PubMed ID: 25625428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.
    Lin JJ; Kennedy E; Sequist LV; Brastianos PK; Goodwin KE; Stevens S; Wanat AC; Stober LL; Digumarthy SR; Engelman JA; Shaw AT; Gainor JF
    J Thorac Oncol; 2016 Nov; 11(11):2027-2032. PubMed ID: 27544060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.